Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Kouji IzumiDepartment of Integrative Cancer Therapy and Urology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8640, Japan.ORCID 0000-0002-8480-9100
Ryuji MatsumotoDepartment of Renal and Genitourinary Surgery, Hokkaido University, Sapporo 060-8638, Japan.ORCID 0000-0001-9363-9054
Yusuke ItoDepartment of Urology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.ORCID 0000-0003-4325-7722
Seiji HoshiDepartment of Urology, Fukushima Medical University School of Medicine, Fukushima City 960-1295, Japan.ORCID 0000-0003-1545-1827
Nobuaki MatsubaraDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.ORCID 0000-0002-9203-4245
Toshinari YamasakiDepartment of Urology, Kobe City Medical Center General Hospital, Kobe 650-0047, Japan.ORCID 0000-0002-3079-6033
Takashi MizowakiDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.ORCID 0000-0002-8135-8746
Atsushi KomaruProstate Center and Division of Urology, Chiba Cancer Center, Chiba 260-0801, Japan.ORCID 0000-0002-6350-3436
Satoshi NomuraNovartis Pharma K.K., Tokyo 105-0001, Japan.
Toru HattoriNovartis Pharma K.K., Tokyo 105-0001, Japan.
Hiroya KambaraNovartis Pharma K.K., Tokyo 105-0001, Japan.
Shaheen AlaneeSenior Clinical Development, RLT Prostate, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Makoto HosonoDepartment of Radiology, Kindai University, Osaka 577-8502, Japan.ORCID 0000-0001-8040-3245
Seigo KinuyaDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan.
Funding
Eckert & Ziegler Radiopharma GmbH Not applicableNovartis Not applicable
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.